Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
